Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Completed · Enrollment 2539
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | 34.5% | n/r | n/r | n/r |
| 5 mg Tirzepatide | n/r | n/r | n/r | n/r |
| 10 mg Tirzepatide | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 90.9% | n/r | n/r | n/r |
Not shown
- 5 mg Tirzepatide: endpoint not reported
- 10 mg Tirzepatide: endpoint not reported